Emcure Pharmaceuticals Ltd (EMCURE)
₹1,928.20
Mkt cap
₹36,566 Cr
P/E ratio
35.50
P/B
7.39
Div yield
0.19%
ROE
20.10%
ROCE
24.00%
EPS (TTM)
₹54.32
Book value
₹261
52W range
1,272–2,010
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]
NSE EMCUREBSE 544210
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−4.05% from high₹1,928
₹1,272+51.61% from low₹2,010
Current
₹1,928.20
Prev close
₹1,925.90
Day
+0.12%
Price performance
1D
+0.12%
1W
+3.93%
1M
−2.54%
3M
+10.52%
6M
+31.45%
1Y
+39.56%
YTD
+34.75%
Financials
Revenue, profit & margin
P/E ratio
35.5×
EMCURE is 5% above the sector median of 34.0×
EMCURE35.5×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,556 | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 | |
| Expenses | 1,261 | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 | |
| Operating Profit | 296 | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 | |
| OPM % | 19% | 20% | 18% | 18% | 19% | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% | |
| Other Income | 15 | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 | |
| Interest | 52 | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 | |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 | |
| Profit before tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 | |
| Tax % | 26% | 26% | 30% | 27% | 26% | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% | |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 | |
| EPS in Rs | 7.21 | 7.69 | 6.27 | 6.36 | 7.95 | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | 15.50 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.54% · closed higher next day 3 of last 9
| Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 13 Aug '24◦ | 8 Nov '24 | 6 Feb '25◦ | 22 May '25◦ | 7 Aug '25 | 11 Nov '25 | 4 Feb '26 | 5 May '26◦ | 6 Aug '26 |
| Earnings day | +0.54% | −3.19% | −5.64% | +9.99% | −1.52% | −3.99% | +1.91% | −1.82% | −1.14% |
| +1 day | +1.78% | −0.37% | −8.73% | +20.18% | −2.57% | −6.25% | −1.59% | −1.51% | +0.99% |
| +5 days | +9.92% | −9.35% | −22.61% | +13.89% | +2.29% | −4.63% | −0.49% | −1.97% | +2.58% |
| +15 days | +13.63% | −4.27% | −25.58% | +16.59% | −2.86% | −2.45% | −5.01% | +2.07% | −4.11% |
| +30 days | +15.81% | −1.33% | −21.69% | +7.25% | −7.40% | −0.01% | −2.35% | +3.72% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202677.83%Promoter
Promoters77.83%0.04
FIIs4.87%1.52
DIIs8.46%2.36
Public8.84%3.85
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| EMCURE | ₹1,927.60 | 35.50 | 36,566 | 0.19% | 292 | +40.45% | 2,580 | +22.85% | 24.02% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports2
Concall transcripts20
Credit ratings6
Announcements5
Intimation Under Regulations 30 And 36(1)(B) Of The SEBI (LODR) Regulations, 2015 1 Sep - Emcure dispatches 45th AGM notice and FY2025-26 annual report; AGM on September 21, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Sep - Intimation of schedule of Investor Meet on Friday, September 04, 2026Announcement under Regulation 30 (LODR)-Credit Rating 1 Sep - CARE reaffirmed Emcure’s bank ratings: AA/Stable and A1+ on ₹2,400 crore facilities.Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Aug - Newspaper Advertisement of Notice of the 45th Annual General Meeting and e-voting informationBusiness Responsibility and Sustainability Reporting (BRSR) 28 Aug - Emcure filed its FY2025-26 BRSR with annual sustainability, governance, workforce, and ESG disclosures.